Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07370-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Miki Yamada und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoadjuvant Therapy, Metabolomics. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: KAKENHI.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Preoperative chemotherapy is a critical component of breast cancer management, yet its effectiveness is not uniform. Moreover, the adverse effects associated with chemotherapy necessitate the identification of a patient subgroup that would derive the maximum benefit from this treatment. This study aimed to establish a method for predicting the response to neoadjuvant chemotherapy in breast cancer patients utilizing a metabolomic approach. METHODS: Plasma samples were obtained from 87 breast cancer patients undergoing neoadjuvant chemotherapy at our facility, collected both before the commencement of the treatment and before the second treatment cycle. Metabolite analysis was conducted using capillary electrophoresis-mass spectrometry (CE-MS) and liquid chromatography-mass spectrometry (LC-MS). We performed comparative profiling of metabolite concentrations by assessing the metabolite profiles of patients who achieved a pathological complete response (pCR) against those who did not, both in initial and subsequent treatment cycles. RESULTS: Significant variances were observed in the metabolite profiles between pCR and non-pCR cases, both at the onset of preoperative chemotherapy and before the second cycle. Noteworthy distinctions were also evident between the metabolite profiles from the initial and the second neoadjuvant chemotherapy courses. Furthermore, metabolite profiles exhibited variations associated with intrinsic subtypes at all assessed time points. CONCLUSION: The application of plasma metabolomics, utilizing CE-MS and LC-MS, may serve as a tool for predicting the efficacy of neoadjuvant chemotherapy in breast cancer in the future after all necessary validations have been completed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606, Japan.
- Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8606, Japan. jinno@med.teikyo-u.ac.jp.
- Institute for Advanced Biosciences, Keio University, 246-2 Mizukami, Kakuganji, Tsuruoka, Yamagata, 997-0052, Japan.
- Institute of Medical Science, Tokyo Medical University, Shinjuku, Shinjuku-ku, Tokyo, 160-8402, Japan.
Förderung
- KAKENHI
Zitieren
APA
Yamada, M., Jinno, H., Naruse, S., Isono, Y., Maeda, Y., Sato, A., Matsumoto, A., Ikeda, T., & Sugimoto, M. (2024). Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07370-2
Vancouver
Yamada M, Jinno H, Naruse S, Isono Y, Maeda Y, Sato A, et al. Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07370-2
BibTeX
@article{Yamada2024,
author = {Yamada, Miki and Jinno, Hiromitsu and Naruse, Saki and Isono, Yuka and Maeda, Yuka and Sato, Ayana and Matsumoto, Akiko and Ikeda, Tatsuhiko and Sugimoto, Masahiro},
title = {Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07370-2}
}
EUVIMED